erythrosine has been researched along with bortezomib in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Chiang, AK; Hui, KF | 1 |
Boháčová, V; Breier, A; Kyca, T; Mišák, A; Pavlíková, L; Poturnayová, A; Šereš, M; Sulová, Z | 1 |
2 other study(ies) available for erythrosine and bortezomib
Article | Year |
---|---|
Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Proliferation; Depsipeptides; DNA Damage; Endoplasmic Reticulum Stress; Enzyme Activation; Female; Fluoresceins; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Peptides, Cyclic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyridines; Reactive Oxygen Species | 2014 |
Insight into Bortezomib Focusing on Its Efficacy against P-gp-Positive MDR Leukemia Cells.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bortezomib; Cell Cycle; Cell Division; Cell Line, Tumor; Deubiquitinating Enzymes; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluoresceins; Gene Expression Regulation, Neoplastic; Genes, cdc; Humans; Inhibitory Concentration 50; Leukemia, Lymphoid; Mice; Neoplasm Proteins; Protease Inhibitors; Proteasome Endopeptidase Complex; Recombinant Proteins; RNA, Messenger; RNA, Neoplasm; Transcription, Genetic; Ubiquitinated Proteins; Vincristine | 2021 |